Pages

AL (primary) amyloidosis and light and heavy chain deposition diseases

AL (primary) amyloidosis and light and heavy chain deposition diseases are clonal plasma cell proliferative disorders characterized by tissue deposits of light chain or heavy chain fragments, leading to organ dysfunction. A minority of patients have or develop multiple myeloma or Waldenstrom's macroglobulinemia.

Further reading
  • Kisilevsky R, Young ID. Pathogenesis of amyloidosis. Baillieres Clin Rheumatol 1994; 8:613.
  • Gallo G, Wisniewski T, Choi-Miura NH, et al. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994; 145:526.
  • Husby G, Stenstad T, Magnus JH, et al. Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis. Clin Immunol Immunopathol 1994; 70:2.
  • Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 1995; 92:4299.
  • Preud'homme JL, Aucouturier P, Touchard G, et al. Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 1994; 46:965.
  • Buxbaum JN, Chuba JV, Hellman GC, et al. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 1990; 112:455.
  • Ganeval D, Noël LH, Preud'homme JL, et al. Light-chain deposition disease: its relation with AL-type amyloidosis. Kidney Int 1984; 26:1.
  • Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12:1482.
  • Clinical Nephrology; 2009; 71:314.
  • Pozzi C, D'Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42:1154.
  • Eulitz M, Weiss DT, Solomon A. Immunoglobulin heavy-chain-associated amyloidosis. Proc Natl Acad Sci U S A 1990; 87:6542.
  • Solomon A, Weiss DT, Murphy C. Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis). Am J Hematol 1994; 45:171.
  • Yazaki M, Fushimi T, Tokuda T, et al. A patient with severe renal amyloidosis associated with an immunoglobulin gamma-heavy chain fragment. Am J Kidney Dis 2004; 43:e23.
  • Mai HL, Sheikh-Hamad D, Herrera GA, et al. Immunoglobulin heavy chain can be amyloidogenic: morphologic characterization including immunoelectron microscopy. Am J Surg Pathol 2003; 27:541.
  • Gono T, Yazaki M, Fushimi T, et al. AH amyloidosis associated with lymphoplasmacytic lymphoma secreting a monoclonal gamma heavy chain carrying an unusual truncated D segment. Am J Kidney Dis 2006; 47:908.
  • Zhou P, Comenzo RL, Olshen AB, et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 2008; 111:3403.
  • Solomon A, Macy SD, Wooliver C, et al. Splenic plasma cells can serve as a source of amyloidogenic light chains. Blood 2009; 113:1501.
  • Harris, AA, Wilkman, AS, Hogan, SL, et al. Amyloidosis and light chain deposition disease in renal biopsy specimens: Pathology, laboratory data, demographics and frequency (abstract). J Am Soc Nephrol 1997; 8:537A.
  • Bellotti V, Merlini G, Bucciarelli E, et al. Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Br J Haematol 1990; 74:65.
  • Perfetti V, Casarini S, Palladini G, et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 2002; 100:948.
  • Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest 1982; 70:453.
  • Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990; 323:508.
  • Rostagno A, Frizzera G, Ylagan L, et al. Tumoral non-amyloidotic monoclonal immunoglobulin light chain deposits ('aggregoma'): presenting feature of B-cell dyscrasia in three cases with immunohistochemical and biochemical analyses. Br J Haematol 2002; 119:62.
  • Noel LH, Droz D, Ganeval D, Grunfeld JP. Renal granular monoclonal light chain deposits: morphological aspects in 11 cases. Clin Nephrol 1984; 21:263.
  • Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991; 324:1845.
  • Keeling J, Teng J, Herrera GA. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest 2004; 84:1322.
  • Myatt EA, Westholm FA, Weiss DT, et al. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci U S A 1994; 91:3034.
  • Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583.
  • Kaplan B, Ramirez-Alvarado M, Sikkink L, et al. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br J Haematol 2009; 144:705.
  • Kaplan B, Livneh A, Gallo G. Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease. Br J Haematol 2007; 136:723.
  • Hurle MR, Helms LR, Li L, et al. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A 1994; 91:5446.
  • Comenzo RL, Wally J, Kica G, et al. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematol 1999; 106:744.
  • Abraham RS, Geyer SM, Price-Troska TL, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 2003; 101:3801.
  • Comenzo RL, Zhang Y, Martinez C, et al. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001; 98:714.
  • Picken MM, Frangione B, Barlogie B, et al. Light chain deposition disease derived from the kappa I light chain subgroup. Biochemical characterization. Am J Pathol 1989; 134:749.
  • Rostagno A, Vidal R, Kaplan B, et al. pH-dependent fibrillogenesis of a VkappaIII Bence Jones protein. Br J Haematol 1999; 107:835.
  • Troussard X, Hurault de Ligny B, Gallet B, et al. Massive systemic amyloidosis associated with light-chain deposition disease. Nephron 1989; 52:139.
  • Arendt BK, Ramirez-Alvarado M, Sikkink LA, et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood 2008; 112:1931.
  • Aucouturier P, Khamlichi AA, Touchard G, et al. Brief report: heavy-chain deposition disease. N Engl J Med 1993; 329:1389.
  • Kambham N, Markowitz GS, Appel GB, et al. Heavy chain deposition disease: the disease spectrum. Am J Kidney Dis 1999; 33:954.
  • Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45.
  • Eder L, Bitterman H. Image in clinical medicine. Amyloid purpura. N Engl J Med 2007; 356:2406.
  • Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia. J Clin Oncol 1993; 11:914.
  • Gertz MA, Kyle RA. Amyloidosis with IgM monoclonal gammopathies. Semin Oncol 2003; 30:325.
  • Terrier B, Jaccard A, Harousseau JL, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine (Baltimore) 2008; 87:99.
  • Wechalekar AD, Lachmann HJ, Goodman HJ, et al. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008; 112:4009.
  • Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357:1083.
  • Guidelines Working Group of UK Myeloma Forum, British Commitee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125:681.
  • Fujita Y, Tsuji-Abe Y, Sato-Matsumura KC, et al. Nail dystrophy and blisters as sole manifestations in myeloma-associated amyloidosis. J Am Acad Dermatol 2006; 54:712.
  • Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A. Localized AL amyloidosis of the colon: an unrecognized entity. Amyloid 2003; 10:36.
  • Tirzaman O, Wahner-Roedler DL, Malek RS, et al. Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc 2000; 75:1264.
  • Domínguez S, Wienberg P, Clarós P, et al. Primary localized nasopharyngeal amyloidosis. A case report. Int J Pediatr Otorhinolaryngol 1996; 36:61.
  • Zeiser R, Mikesch K, Fisch P, et al. Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip. Br J Haematol 2004; 125:679.

No comments:

Post a Comment